E-7386 clinical trials
Also written E7386.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2017
How each study uses E-7386 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- E7386
- 6
Studies by the year they started
7 studies that test it; most in 2019 (3)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 3 |
| 2021 | 2 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test E-7386.
- Mar 2027A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid TumorPhase 1/2 · Eisai Inc.
- Mar 2027Study of E7386 in Participants With Selected Advanced NeoplasmsPhase 1 · Eisai Inc.
- Mar 2027A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)Phase 1 · Eisai Co., Ltd.
Studies
Open first, then newest update. How each study uses E-7386 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid TumorActive, not recruitingPhase 1/2Eisai Inc.NCT04008797Written as E7386
- Study of E7386 in Participants With Selected Advanced NeoplasmsActive, not recruitingPhase 1Eisai Inc.NCT03264664Written as E7386
- A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)Active, not recruitingPhase 1Eisai Co., Ltd.NCT03833700Written as E7386
- A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid TumorsCompletedPhase 1/2Eisai Inc.NCT05091346Written as E7386
- A Study to Evaluate the Relative Bioavailability of E7386 Following Oral Administration of Targeted Release (TR) Tablets Compared to an E7386 Immediate Release (IR) Tablet in Healthy Adult ParticipantsWithdrawnPhase 1Eisai LimitedNCT04840927Written as E7386
- A Study to Determine the Absolute Bioavailability and the Absorption, Metabolism, and Elimination Properties of Carbon-14 (14C)E7386 in Healthy Male ParticipantsCompletedPhase 1Eisai LimitedNCT05607537Written as E7386 Tablet
- A Food-Effect Study of E7386 in Healthy ParticipantsCompletedPhase 1Eisai Inc.NCT03996226Written as E7386
Codes
What other systems call E-7386 · ClinicalTrials.gg INT001627
- MeSH (NLM) C000717377E-7386Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) I0DX1FG55YE-7386Confirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000717377 | E-7386 | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | I0DX1FG55Y | E-7386 | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.